This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: atorvastatin

May 2019 Br J Cardiol 2019;26:52

In briefs

BJC Staff

Abstract

Stat tests loaded into the VITROS XT 7600 Moderate alcohol consumption does not protect against stroke Blood pressure and stroke risk increase steadily with increasing alcohol intake, and previous claims that one to two alcoholic drinks a day might protect against stroke are not borne out by new evidence from a genetic study involving 160,000 adults. Studies of East Asian genes, where two common genetic variants strongly affect what people choose to drink, show that alcohol itself directly increases blood pressure and the chances of having a stroke, according to a new study published in The Lancet (doi: 10.1016/S0140-6736(18)31772-0). Researc

| Full text

October 2017

ESC 2017: REVEAL – modest beneficial effects with anacetrapib

BJC Staff

Abstract

Presented in a hotline session by Dr Martin Landray (University of Oxford), the trial’s co-principal investigator, and simultaneously published in the New England Journal of Medicine (https://doi.org/10.1056/NEJMoa1706444), this large-scale, placebo-controlled study was carried out on 30,449 patients with cardiovascular disease, who were all receiving lipid-lowering treatment with atorvastatin. Those patients also receiving anacetrapib (100 mg once daily) showed a significant reduction in the primary outcome, the risk of major coronary events (coronary death, myocardial infarction or coronary re-vascularisation) by 9% relative to those pati

| Full text
News from the 2010 Congress of the European Society of Cardiology

September 2010 Br J Cardiol 2010;17:211-14

News from the 2010 Congress of the European Society of Cardiology

Abstract

Highlights of this year’s European Society of Cardiology Congress, held in Stockholm, Sweden, from August 28th to September 1st included a new drug which benefits heart failure by slowing heart rate, and more exciting results from oral compounds that could replace warfarin in various indications. Highlights of this year’s European Society of Cardiology Congress, held in Stockholm, Sweden, from August 28th to September 1st included a new drug which benefits heart failure by slowing heart rate, and more exciting results from oral compounds that could replace warfarin in various indications. SHIFT: ivabradine shows benefit in heart failure

| Full text

November 2006 Br J Cardiol 2006;13:386-90

News from the Scientific Sessions 2006 of the American Heart Association

BJCardio editorial team

Abstract

No content available

| Full text

March 2006 Br J Cardiol 2006;13:90-8

American College of Cardiology 55th Annual Scientific Session

BJCardio editorial team

Abstract

No content available

| Full text

April 2002 Br J Cardiol 2002;9:193-4

Statins: myalgia and myositis

Anthony S Wierzbicki

Abstract

No content available

| Full text

For healthcare professionals only

Add Banner

Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now